To understand the complication and histopathological characteristics between the Silk Fibroin/Polyurethanes (SF/PU) and the host response, and to unveil the compatibility of the patch in diabetes individuals.
Methods
Rats were divided into DM and control (CT) groups, and the DM group was induced with streptozotocin. All groups underwent the SF/PU patch implantation in the abdominal aorta, and the implanted patches were evaluated at one, two, three, and four weeks after implantation.
Results
DM group had more fibrosis formation and a delayed endothelialization compared to the CT group. There was no evidence of chronic inflammation in both DM and CT groups.
Conclusions
Fibrosis in hyperglycemic individuals could promote the formation of new vascular structures in the implanted patch such as endothelial and vascular smooth muscle cells. In summary, the SF/PU patch was no serious complications when implanted under hyperglycemia, and the patch was suitable to implant in diabetes mellitus.
AssarMEAnguloJRodríguez-MañasL.Diabetes and ageing-induced vascular inflammation. J Physiol2016; 594: 2125–2146.
2.
HadiHARSuwaidiJA.Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag2007; 3: 853–876.
3.
HamiltonSJWattsGF.Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment. Rev Diabet Stud2013; 10: 133–156.
4.
RobertsACPorterKE.Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Diab Vasc Dis Res2013; 10: 472–482. 2013/09/03. DOI: 10.1177/1479164113500680.
5.
SenaCMPereiraAMSeiçaR.Endothelial dysfunction - a major mediator of diabetic vascular disease. Biochim Biophys Acta2013; 1832: 2216–2231.
6.
FujimotoKLGuanJOshimaH, et al. In vivo evaluation of a porous, elastic, biodegradable patch for reconstructive cardiac procedures. Ann Thorac Surg2007; 83: 648–654.
7.
TudoracheIKostinSMeyerT, et al. Viable vascularized autologous patch for transmural myocardial reconstruction. Eur J Cardiothorac Surg2009; 36: 306–311; discussion 311.
8.
KunduBRajkhowaRKunduSC, et al. Silk fibroin biomaterials for tissue regenerations. Adv Drug Deliv Rev2013; 65: 457–470.
9.
OmenettoFGKaplanDL.New opportunities for an ancient material. Science2010; 329: 528–531.
10.
SultanMTLeeOJKimSH, et al. Silk fibroin in wound healing process. Adv Exp Med Biol2018: 1077: 115–126.
11.
ParkHSGongMSParkJH, et al. Silk fibroin-polyurethane blends: physical properties and effect of silk fibroin content on viscoelasticity, biocompatibility and myoblast differentiation. Acta Biomater2013; 9: 8962–8971.
12.
NakazawaYAsanoANakazawaCT, et al. Structural characterization of silk-polyurethane composite material for biomaterials using solid-state NMR. Polym J2012; 44: 802–807.
13.
ShimadaKHiguchiAKuboR, et al. The effect of a silk fibroin/polyurethane blend patch on rat vessels. Organogenesis2017; 13: 115–124.
14.
ChantawongPTanakaTUemuraA, et al. Silk fibroin-Pellethane® cardiovascular patches: effect of silk fibroin concentration on vascular remodeling in rat model. J Mater Sci Mater Med2017; 28: 191–2017.
15.
MeinelLKaplanDL.Silk constructs for delivery of musculoskeletal therapeutics. Adv Drug Deliv Rev2012; 64: 1111–1122.
16.
NakazawaCTHiguchiAAsanoA, et al. Solid-state NMR studies for the development of non-woven biomaterials based on silk fibroin and polyurethane. Polym J2017; 49: 583–586.
17.
AytemizDFukudaYHiguchiA, et al. Compatibility evaluation of non-woven sheet composite of silk fibroin and polyurethane in the wet state. Polymers2018; 10: 874.
18.
BoniakowskiAEKimballASJacobsBN, et al. Macrophage-mediated inflammation in normal and diabetic wound healing. J Immunol2017; 199: 17–24.
19.
HonnegowdaTMKumarPUdupaEGP, et al. Role of angiogenesis and angiogenic factors in acute and chronic wound healing. Plast Aesthet Res2015; 2: 243–249.
20.
ShiGJShiGRZhouJY, et al. Involvement of growth factors in diabetes mellitus and its complications: a general review. Biomed Pharmacother2018; 101: 510–527.
21.
AvogaroAAlbieroMMenegazzoL, et al. Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care2011; 34: S285–S290.
22.
LiuBFMiyataSKojimaH, et al. Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end products. Diabetes1999; 48: 2074–2082.
23.
LecubeAPachónGPetrizJ, et al. Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement. PloS One2011; 6: e23366–e23366.
24.
PavlouSLindsayJIngramR, et al. Sustained high glucose exposure sensitizes macrophage responses to cytokine stimuli but reduces their phagocytic activity. BMC Immunol2018; 19: 24.
25.
KitpipatkunPMatsuuraKShimadaK, et al. Key factors of diastolic dysfunction and abnormal left ventricular relaxation in diabetic rats. J Med Ultrasonics2020; 47: 347–356.
26.
NomaTMizushigeKYaoL, et al. Alteration in aortic wall stiffness and accumulation of collagen during the prediabetic stage of type II diabetes mellitus in rats. Jpn Circ J1999; 63: 988–993.
27.
SunHZhongMMiaoY, et al. Impaired elastic properties of the aorta in fat-fed, streptozotocin-treated rats. Cardiology2009; 114: 107–113.
28.
RoostaluUWongJKF.Arterial smooth muscle dynamics in development and repair. Dev Biol2018; 435: 109–121.
